3,5-Difluorophenylboronic acid

We are 3,5-Difluorophenylboronic acid CAS:156545-07-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:3,5-Difluorophenylboronic acid
CAS.NO:156545-07-2
Synonyms:3,5-Difluorophenylboronic acid
(3,5-difluorophenyl)boronic acid
Molecular Formula:C6H5BF2O2
Molecular Weight:157.91100
 
Physical and Chemical Properties:
Density:1.35
Melting point:210-217ºC
Boiling point:266.9ºC
Flash point:115.2ºC
Index of Refraction:1.562
 
Specification:
Appearance:White to light yellow powder
Assay:≥99.0%
Moisture:≤0.2%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate

3,5-Difluorophenylboronic acid


Related News: It is estimated that the size of China’s CMO market has reached about USD 5 billion. With the implementation and further implementation of the MAH system (the core is to separate drug marketing authorization from drug production authorization) in China, it is expected to promote the outbreak of the domestic drug CMO industry. It will grow at a rate of 20% to 30%, of which patented APIs occupy a larger proportion.4-Carboxyphenylboronic acid According to statistics, in 2017, China’s total production of chemical drugs reached 3.478 million tons, a year-on-year increase of 1.6%. The main business income showed a steady increase, from 328.972 billion yuan in 2012 to 573.475 billion yuan in 2017. The total profit was 48.644 billion yuan, but profit margins remain low (8.48% in 2017).1,7-Dibromoheptane CAS:4549-31-9 It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing.2,8-bis (trifluorometil) -1H-quinolin-4-ona CAS:35853-41-9 Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route.

Related Products
Product Name
(2S)-2-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]amino]propanoic acid View Details
N,N-Dimethylallylamine View Details
7-Methoxy-1-tetralone View Details
5,6-Dimethoxy-2-(4-Piperidinylmethyl)-1-Indanone Hydrochloride manufacturer 6-Bromo-2,3-Dihydro-4H-Chromen-4-One manufacturer Dienedione manufacturer Cyclopropanesulfonamide manufacturer 2-Bromo-5-fluorobenzoic acid manufacturer